Jim Cramer Says It's 'Still Not Too Late' To Buy This Energy Stock

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is taking a "hard pass" on Surgery Partners, Inc. SGRY. "That industry has been up and down and up and down," he added.

Surgery Partners recently reaffirmed its 2023 adjusted EBITDA guidance of $436 million to $440 million and revenue guidance of $2.85 billion.
When asked about CRISPR Therapeutics AG CRSP, he said, "I like those guys, but I have no illusions. they’re losing a lot of money, and we don’t like to recommend stocks that are losing a lot of money."

The FDA recently approved CRISPR Therapeutics /Vertex Pharmaceutical’s Casgevy (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older.

Cramer said he hasn’t liked Vodafone Group Public Limited Company VOD in 20 years, and "it’s really rewarded my dislike."

Vodafone and Microsoft have announced a strategic alliance for the next 10 years. This collaboration aims to extend digital services to more than 300 million businesses and consumers.

Don’t forget to check out our premarket coverage here

Cramer said he needs to do some work on DigitalOcean Holdings, Inc. DOCN. "I just don’t know why that stock’s acting as poorly as it does, given the fact that the business is good," he added.

DigitalOcean recently named Paddy Srinivasan as its chief executive officer.

The "Mad Money" host said it is "still not too late" to buy Energy Transfer LP ET.

Energy Transfer recently announced an increase in quarterly cash distribution.

MP Materials Corp. MP just "never lifts," Cramer said, "I’m not against it."

Price Action: